XML 40 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Schedule of Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Cash

 

$

90,899

 

 

$

88,046

 

Commercial paper

 

 

12,000

 

 

 

 

Money market funds

 

 

171,628

 

 

 

590,347

 

Total cash and cash equivalents

 

$

274,527

 

 

$

678,393

 

 

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments

The Company’s investments consist of available-for-sale debt investments and marketable equity investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands):

 

 

 

September 30, 2021

 

 

 

Amortized Cost

 

 

Gross Unrealized

Holding Gains

 

 

Gross Unrealized

Holding Losses

 

 

Fair Value

 

Corporate bonds

 

$

127,005

 

 

$

35

 

 

$

(46

)

 

$

126,994

 

Commercial paper

 

 

95,402

 

 

 

 

 

 

 

 

 

95,402

 

U.S. government bonds

 

 

73,119

 

 

 

5

 

 

 

(16

)

 

 

73,108

 

Agency bonds

 

 

23,399

 

 

 

4

 

 

 

(4

)

 

 

23,399

 

Asset-backed securities

 

 

27,261

 

 

 

2

 

 

 

(7

)

 

 

27,256

 

Foreign government bonds

 

 

8,127

 

 

 

 

 

 

 

 

 

8,127

 

Equity investments

 

 

118

 

 

 

107

 

 

 

 

 

 

225

 

Total investments

 

$

354,431

 

 

$

153

 

 

$

(73

)

 

$

354,511

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

 

Amortized Cost

 

 

Gross Unrealized

Holding Gains

 

 

Gross Unrealized

Holding Losses

 

 

Fair Value

 

Bond and mutual funds

 

$

8,147

 

 

$

 

 

$

(3

)

 

$

8,144

 

Equity investments

 

 

125

 

 

 

119

 

 

 

 

 

 

244

 

Total investments

 

$

8,272

 

 

$

119

 

 

$

(3

)

 

$

8,388

 

Schedule of Inventory

Inventories consisted of the following (in thousands):

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Raw materials

 

$

820

 

 

$

2,303

 

Work-in-progress

 

 

20,662

 

 

 

8,114

 

Finished goods

 

 

7,833

 

 

 

6,113

 

Total inventories

 

$

29,315

 

 

$

16,530

 

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Unbilled contract assets

 

$

15,003

 

 

$

2,147

 

Deferred revenues from associated contracts

 

 

(7,003

)

 

 

(2,147

)

Net unbilled contract assets

 

 

8,000

 

 

 

 

Prepaid assets

 

 

6,598

 

 

 

8,353

 

Other current assets

 

 

7,090

 

 

 

1,807

 

Total prepaid expenses and other current assets

 

$

21,688

 

 

$

10,160

 

Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Leasehold improvements

 

$

102,843

 

 

$

102,006

 

Laboratory equipment

 

 

18,809

 

 

 

18,143

 

Machinery

 

 

8,234

 

 

 

8,312

 

Computer equipment

 

 

9,262

 

 

 

9,545

 

Furniture and fixtures

 

 

6,175

 

 

 

6,128

 

Construction in progress

 

 

1,920

 

 

 

760

 

Total property and equipment

 

$

147,243

 

 

$

144,894

 

Less: accumulated depreciation

 

 

(118,191

)

 

 

(111,247

)

Property and equipment, net

 

$

29,052

 

 

$

33,647

 

Schedule of Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following (in thousands):

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Preclinical and clinical trial accruals

 

$

64,212

 

 

$

44,113

 

Payroll and related accruals

 

 

20,121

 

 

 

22,800

 

Contract liabilities to pharmaceutical distributors

 

 

10,335

 

 

 

15,137

 

Accrued co-promotion expenses - current

 

 

27,071

 

 

 

11,537

 

Roxadustat profit share to AstraZeneca

 

 

7,764

 

 

 

7,007

 

Property taxes and other taxes

 

 

11,532

 

 

 

5,970

 

Professional services

 

 

4,565

 

 

 

4,869

 

Other

 

 

5,746

 

 

 

6,900

 

Total accrued and other current liabilities

 

$

151,346

 

 

$

118,333

 

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following (in thousands):

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Accrued long-term co-promotion expenses

 

$

13,514

 

 

$

27,424

 

Other long-term tax liabilities

 

 

9,120

 

 

 

8,675

 

Other

 

 

1,688

 

 

 

2,690

 

Total other long-term liabilities

 

$

24,322

 

 

$

38,789